Role of osteoblast suppression in multiple myeloma

Journal of Cellular Biochemistry

Volumn 98, Issue 1, 2006, Pages 1-13

  Stewart, James Peter ^a   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

DKK1; FRZB; Multiple myeloma; Osteoblast; Osteoclast; Wnt

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; THALIDOMIDE; WNT PROTEIN;

BONE PAIN; CELL INTERACTION; HEMATOPOIESIS; HUMAN; HYPERCALCEMIA; MICROENVIRONMENT; MULTIPLE MYELOMA; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PLASMA CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD COMPRESSION; STEM CELL TRANSPLANTATION; TUMOR GROWTH;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; PLASMA CELLS; SIGNAL TRANSDUCTION;

EID: 33645979662     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20774     Document Type: Review

References (69)

1. Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Briwen K, Heickendorff L, Nielsen JL, Eriksen EF. 2000. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64:121-129.
2. Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K. 2002. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis 19:583-591.
3. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC. 2003. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 18:1088-1098.
4. Barlogie B, Beck T. 1993. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 11:88-94.
5. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P, Alexandre C. 1989. Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone lesions. J Clin Oncol 7:1909-1914.
6. Bergsagel PL, Kuehl WM. 2005. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338.
7. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521.
8. Calvani N, Cafforio P, Silvestris F, Dammacco F. 2005. Functional osteoclast-like transformation of cultured human myeloma cells. Brit J Haematol 130:926-938.
9. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846.
10. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F. 2004. Induction of Dickkopf-1, a negative regulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 24:6021-6027.
11. Das SK, Tan J, Raja S, Halder J, Paria BC, Dey SK. 2000. Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta. J Biol Chem 275:28834-28843.
12. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan NJ, Anderson KC. 2003. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102:4504-4511.
13. Day TF, Guo X, Garrett-Beal L, Yang Y. 2005. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8:739-750.
14. De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B. 2001. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98:771-780.
15. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargren M, Pals ST. 2004. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci 101:6122-6127.
16. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. 2002. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 3:CD003188.
17. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, Yoon K, Cook MJ, Willert K, Gaiano N, Reya T. 2005. Integration of Notch and Wnt Signaling in hematopoietic stem cell maintenance. Nat Immunol 6:314-322.
18. Ely SA, Knowles DM. 2002. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 160:1293-1299.
19. Erhlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N. 2005. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106:1407-1414.
20. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA. 1999. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 274:19465-19472.
21. Fox SW, Lovibond AC. 2005. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 243:19-26.
22. Franz-Odendaal TA, Hall BK, Witten PE. 2005. Buried alive: How osteoblasts become osteocytes. Dev Dyn Advanced electronic publication
23. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitx W, Kim KB, Hu S, Crews CM, Mundy GR. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771-1782.
24. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. Canonical Wnt signalling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem 280:33132-33140.
25. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano S, Svaldi M, Rizzoli V. 2005. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106:2472-2483.
26. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. 2005. Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764.
27. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523.
28. Gonzalez-Sancho JM, Aguilera O, Garcia JM, Pendas-Franco N, Pena C, Cal S, Garcia de Herreros A, Bonilla F, Munoz A. 2005. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 24: 1098-1103.
29. Gregory CA, Singh H, Perry AS, Prockop DJ. 2003. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 278:28067-28078.
30. Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, Prockop DJ. 2005a. Dkk-1-sythetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem 280:2309-2323.
31. Gregory CA, Gunn WG, Reyes E, Smolarz AJ, Munoz J, Spees JL, Prockop DJ. 2005b. How Wnt signalling affects bone repair by mesenchymal stem cells from the bone marrow. Ann NY Acad Sci 1049:97-106.
32. Gu G, Mulari M, Peng Z, Hentunen TA, Vaananen HK. 2005. Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun 335:1095-1101.
33. Guise TA, Yin JJ, Thomas RJ, Dallas M, Cui Y, Gillespie MT. 2002. Parathyroid hormone-related protein (PTHrP)-1(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30:670-676.
34. Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. 2005. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and IL-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells (Epub Nov 17, 2005).
35. Guo J, Bringhurst FR, Kronenberg HM. 2004. α1 collagen promoter-directed overexpression of Dkk1 in mice causes dwarfism and very short limbs. 26th Annual Meeting of the American Society for Bone and Mineral Research. Presentation Number: 1018
36. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. 2005. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 65:7554-7560.
37. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309:1074-1078.
38. Karadag A, Scutt AM, Croucher PI. 2000. Human myeloma cells promote the recruitment of osteoblast precursors: Mediation by interleukin-6 and soluble interleukin-6 receptor. J Bone Miner Res 15:1935-1943.
39. Kawano Y, Kypta R. 2003. Secreted antagonists of the Wnt signaling pathway. J Cell Sci 116:2627-2634.
40. Kishimoto T. 2005. Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1-21.
41. Kozlow W, Guise TA. 2005. Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10:169-180.
42. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, Nusse R, Kuo CJ. 2004. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci 101:266-271.
43. Lacy MQ, Gertz MA, Hanson CA, Inwards DJ, Kyle RA. 1997. Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 56:288-293.
44. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. 2004. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103:2308-2315.
45. Li X, Liu P, Liu W, Maye P, Zhang J, Zhang Y, Hurley M, Guo C, Boskey A, Sun L, Harris SE, Rowe DW, Ke HZ, Wu D. 2005. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37:945-953.
46. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19.
47. Maricic M. 2005. Glucocorticoid-induced osteoporosis: Treatment options and guidelines. Curr Osteoporos Rep 3:25-29.
48. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. 1993. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 106:128-135.
49. Nusse R. 2005. Wnt signaling in disease and in development. Cell Res 15:28-32.
50. Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. 2005. Glucocorticoid suppresses the canonical wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 329:177-181.
51. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T. 2005. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106:3160-3165.
52. Oyajobi BO, Garrett IR, Gupta A, Banerjee M, Esparza X, Flores A, Sterling J, Rossini G, Zhao M, Mundy GR. 2004. Role of Dickkopf 1 (Dkk) in myeloma bone disease and modulation by the proteasome inhibitor velcade. 26 th Annual Meeting of the American Society for Bone and Mineral Research. Presentation Number: 1011
53. Qiang YW, Endo Y, Rubin J, Rudikoff S. 2003. Wnt signaling in B-cell neoplasia. Oncogene 22:1536-1545.
54. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J, Jr., Rudikoff S. 2005. Wnts induce migration and invasion of myeloma plasma cells. Blood 106:1786-1793.
55. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. 2003. BMP-2 controls alkaline phosphatase expression and osteoblast mieralization by a Wnt autocrine loop. J Bone Miner Res 18:1842-1853.
56. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. 2003. A role for Wnt signaling in self renewal of haematopoietic stem cells. Nature 423:409-414.
57. Roodman GD. 2004. Mechanisms of bone metastasis. N Engl J Med 350:1655-1664.
58. Shaughnessy J, Zhan F, Kordsmeier B, Randolph C, McCastlain K, Barlogie B. Gene expression profiling after short term in-vivo treatment identifies potential mechanisms of action of current drugs used to treat multiple myeloma. Blood 2002; 100:781a.
59. Smith E, Frenkel B. 2005. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3 beta-dependent and -independent manner. J Biol Chem 280:2388-2394.
60. Takai E, Mauck RL, Hung CT, Guo XE. 2004. Osteocyte viability and regulation of osteoblastic function in a 3D trabecular bone explant under dynamic hydrostatic pressure. J Bone Miner Res 19:1403-1410.
61. Tian E, Zhan F, Walker R, Rasmussen E, Yupo M, Barlogie B, Shaughnessy JD. 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New Eng J Med 349: 2483-2494.
62. Vaes BL, Dechering KJ, van Someren EP, Hendriks JM, van de Ven CJ, Feijen A, Mummery CL, Reinders MJ, Olijve W, van Zoelen EJ, Steegenga WT. 2005. Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 36:803-811.
63. Wang J, Shou J, Chen X. 2000. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 19:1843-1848.
64. Yaccoby S, Zhan F, Barlogie B, Shaughnessy JD. 2005. Blocking DKK1 activity in primary myeloma-bearing SCID-rab mice is associated with increased osteoblastic activity and bone formation, and inhibition of tumor growth. 26 th Annual Meeting of the American Society for Bone and Mineral Research. Presentation Number: 1125.
65. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. 2005. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Hematol 131:71-73.
66. Zhan F, Hardin J, Kordsmeier B, Blumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. 2002. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757.
67. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J, Jr. 2003. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101:1128-1140.
68. Zhan F, Barlogie B, Huang Y, Rasmussen E, Sawyer J, Santra M, Walker R, Tricot G, Crowley J, Anaissie E, Shaughnessy J. 2004. The transcriptome of multiple myeloma (MM) defines disease subgroups with distinct genetic and clinical features. Blood 104: Abstract 76.
69. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. 2003. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425:836-841.